On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Shares Plunge on Top-line Phase 2 Data of NSI-189 for MDD

Company: Neuralstem, Inc. (CUR)
Category: News

Shares of Neuralstem (NASDAQ: CUR) plummeted 57% following the company’s release of top-line data from its exploratory phase 2 clinical trial on the efficacy of NSI-189 for Major Depressive Disorder (MDD). The trial did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS). The trial evaluated NSI-189 at 40 mg once daily and 40 mg twice daily compared to placebo. The 40 mg once daily dose was directionally positive on the MADRS. One of the trial’s two secondary endpoints, the patient-rated Symptoms of Depression Questionnaire (SDQ), achieved statistical significance with the once daily dose in the overall sequential parallel comparison design (SPCD) analysis. “The directionally positive signals across multiple depression scales are encouraging and we look forward to further evaluation of the full dataset in the coming months,” Neuralstem chairman and CEO Rich Daly stated in the news release.

To view the full press release, visit: http://nnw.fm/HCi3R

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is the lead compound in Neuralstem’s neurogenic small molecule program. NSI-566 is a stem cell therapy being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology. For more information, visit www.neuralstem.com.

More from NetworkNewsBreaks

Flex Pharma, Inc.’s (NASDAQ: FLKS) FLX-787 Receives Fast Track Designation from FDA to Treat Severe ALS Cramps

ORHub, Inc. (ORHB) Announces Launch of Neurosurgery Service Line

Eltek (NASDAQ: ELTK) Shares Swell on $3M Order by Governmental Authority

About NetworkNewsBreaks

NetworkNewsBreaks, a service of NetworkNewsWire (NNW), delivers rapid fire market updates and summaries of corporate news and information. NetworkNewsBreaks keeps you up-to-date on US markets and market moving public companies. These compact synopses provide snapshots of position, opportunity and momentum. NetworkNewsBreaks is a complimentary service of NetworkNewsWire.

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217